Who founded Adrenomed AG?

Adrenomed AG was founded by Gerald Moeller in 2009.

Who are Adrenomed AG's investors?

Adrenomed AG's investors include Brandenburg Kapital, Catalyze Capital, HBM Healthcare Investments, HBM Partners, VU Venture Partners.

Where is Adrenomed AG headquartered?

Adrenomed AG is headquartered in Hennigsdorf, DE.

Adrenomed AG

Hennigsdorf, DE · Founded 2009 · 5 known investors

Find your way into Adrenomed AG

Paths you didn't know you had: your email and LinkedIn already hold routes to the Adrenomed AG team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication. It applies a biomarker-guided precision medicine approach to identify patients most likely to benefit and is based in the Berlin area of Germany.

Biotech Healthtech Medical Devices

Founders & leadership

Adrenomed AG was founded in 2009 by Gerald Moeller.

Gerald MoellerCo-founder and former CEO of AdrenoMed; Supervisory Board member

Richard Jones Chief Executive Officer (CEO)Richard Jones has held CEO positions at small biotechnology companies and senior roles at major pharmaceutical firms, with expertise spanning rare diseases, oncology, hematology, cell and gene therapies, and infectious diseases across drug discovery, development, manufacturing, and commercialization.

David GermonpréChief Financial Officer (CFO)

Investors · 5

Brandenburg Kapitallisted by Brandenburg KapitalPotsdam · $108K – $5.4M

Catalyze Capitallisted by Catalyze CapitalAmsterdam · $1.6M

HBM Healthcare Investmentslisted by HBM Healthcare InvestmentsZug

How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us

HBM Partnerslisted by HBM PartnersZug · $5M – $50M

How we know: HBM Partners's portfolio page · Not right? Tell us

VU Venture Partnerslisted by VU Venture PartnersSan Francisco · $200K – $1M

How we know: the VCSheet dataset · Not right? Tell us

Frequently asked questions

What does Adrenomed AG do?: AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication. It applies a biomarker-guided precision medicine approach to identify patients most likely to benefit and is based in the Berlin area of Germany.
Who founded Adrenomed AG?: Adrenomed AG was founded by Gerald Moeller in 2009.
Who are Adrenomed AG's investors?: Adrenomed AG's investors include Brandenburg Kapital, Catalyze Capital, HBM Healthcare Investments, HBM Partners, VU Venture Partners.
Where is Adrenomed AG headquartered?: Adrenomed AG is headquartered in Hennigsdorf, DE.